NCT07183189 2025-12-18
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
Clinical Trials
13 trialsNCT04923906 2024-11-25
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04687241 2024-11-07
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT06043973 2023-09-21
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital
Phase 3 Recruiting
NCT05800223 2023-04-05
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China
Phase 3 Recruiting
NCT05768490 2023-03-14
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Sun Yat-sen University
Phase 3 Recruiting
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04951635 2022-06-16
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04762459 2022-02-24
APEX
ChineseAMS
Phase 3 Enrolling by invitation
NCT04951648 2021-07-07
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04500704 2020-08-05
ACROSS1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04500717 2020-08-05
ACROSS2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown